adalimumab-aacf (Idacio) vs etanercept

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriatic Arthritis

Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline

adalimumab-aacf (Idacio)

Marketed by Fresenius SE & Co. KGaA

Approved in Psoriatic Arthritismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

etanercept · Enbrel

Marketed by Amgen and partners

Approved in Psoriatic Arthritisfusion protein
Reliable signal

NCT00317499 · Phase 3 · completed

Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and week 24): ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) (met)

Result source: NCT02376790

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aacf (Idacio)etanercept
ACR20—Not reported60.9% vs 50.7%vs Methotrexatewk 24 · n 284NCT02376790
15 other results
  • 65% vs 50.7% wk 24 · n 283 · Phase 3 · primary NCT02376790
  • 83.1% vs 70.7% wk 48 · n 284 · Phase 3 · secondary NCT02376790
  • 80.4% vs 70.7% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 77% vs 66.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 74.2% vs 66.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 67.6% vs 56.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 71.9% vs 56.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 69.5% vs 58.5% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 71.8% vs 58.5% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 65.5% vs 46.8% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 70.3% vs 46.8% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 60.2% vs 46.5% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 60.8% vs 46.5% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 44.3% vs 25% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 46.4% vs 25% wk 4 · n 283 · Phase 3 · secondary NCT02376790
ACR50—Not reported63% vs 49.3%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 60.2% vs 49.3% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 57.3% vs 41.8% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 56% vs 41.8% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 44.4% vs 30.6% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 45.7% vs 30.6% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 43.8% vs 29.2% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 43.4% vs 29.2% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 40.4% vs 16.9% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 39.2% vs 16.9% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 31.3% vs 15.1% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 30.1% vs 15.1% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 16.5% vs 6% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 18.8% vs 6% wk 4 · n 283 · Phase 3 · secondary NCT02376790
PASI 75—Not reported—Not posted · NCT00317499
Minimal disease activity—Not reported51.3% vs 35.8%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 53.2% vs 35.8% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 43.5% vs 30.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 46.7% vs 30.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 35.9% vs 22.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 35.7% vs 22.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 39.5% vs 25.7% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 39.1% vs 25.7% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 29.9% vs 11.6% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 29.1% vs 11.6% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 9.4% vs 3% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 7.4% vs 3% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 11.1% vs 5.7% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 12.6% vs 5.7% wk 4 · n 283 · Phase 3 · secondary NCT02376790
HAQ-DI, change—Not reported-0.6 vs -0.5vs Methotrexatewk 48 · n 284NCT02376790
15 other results
  • -0.6 vs -0.5 wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 258 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 257 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.3 wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 283 · Phase 3 · secondary NCT02376790

ACR20

adalimumab-aacf (Idacio)
—Not reported
etanercept
60.9% vs 50.7%vs Methotrexatewk 24 · n 284NCT02376790
15 other results
  • 65% vs 50.7% wk 24 · n 283 · Phase 3 · primary NCT02376790
  • 83.1% vs 70.7% wk 48 · n 284 · Phase 3 · secondary NCT02376790
  • 80.4% vs 70.7% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 77% vs 66.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 74.2% vs 66.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 67.6% vs 56.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 71.9% vs 56.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 69.5% vs 58.5% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 71.8% vs 58.5% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 65.5% vs 46.8% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 70.3% vs 46.8% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 60.2% vs 46.5% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 60.8% vs 46.5% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 44.3% vs 25% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 46.4% vs 25% wk 4 · n 283 · Phase 3 · secondary NCT02376790

ACR50

adalimumab-aacf (Idacio)
—Not reported
etanercept
63% vs 49.3%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 60.2% vs 49.3% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 57.3% vs 41.8% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 56% vs 41.8% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 44.4% vs 30.6% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 45.7% vs 30.6% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 43.8% vs 29.2% wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • 43.4% vs 29.2% wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • 40.4% vs 16.9% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 39.2% vs 16.9% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 31.3% vs 15.1% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 30.1% vs 15.1% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 16.5% vs 6% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 18.8% vs 6% wk 4 · n 283 · Phase 3 · secondary NCT02376790

PASI 75

adalimumab-aacf (Idacio)
—Not reported
etanercept
—Not posted · NCT00317499

Minimal disease activity

adalimumab-aacf (Idacio)
—Not reported
etanercept
51.3% vs 35.8%vs Methotrexatewk 48 · n 284NCT02376790
13 other results
  • 53.2% vs 35.8% wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • 43.5% vs 30.3% wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • 46.7% vs 30.3% wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • 35.9% vs 22.9% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 35.7% vs 22.9% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 39.5% vs 25.7% wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • 39.1% vs 25.7% wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • 29.9% vs 11.6% wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • 29.1% vs 11.6% wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • 9.4% vs 3% wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • 7.4% vs 3% wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • 11.1% vs 5.7% wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • 12.6% vs 5.7% wk 4 · n 283 · Phase 3 · secondary NCT02376790

HAQ-DI, change

adalimumab-aacf (Idacio)
—Not reported
etanercept
-0.6 vs -0.5vs Methotrexatewk 48 · n 284NCT02376790
15 other results
  • -0.6 vs -0.5 wk 48 · n 283 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.5 wk 36 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.4 wk 24 · n 258 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 24 · n 257 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 16 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.4 wk 16 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 12 · n 284 · Phase 3 · secondary NCT02376790
  • -0.5 vs -0.3 wk 12 · n 283 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 284 · Phase 3 · secondary NCT02376790
  • -0.4 vs -0.3 wk 8 · n 283 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 284 · Phase 3 · secondary NCT02376790
  • -0.3 vs -0.2 wk 4 · n 283 · Phase 3 · secondary NCT02376790
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-aacf (Idacio): no structured comparison results are available for Psoriatic Arthritis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-aacf (Idacio): 0 of 4 rows · etanercept: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricetanercept
Dropout rate
18.7%Etanercept + Methotrexatea
NCT02376790 · Phase 3 · combination
show 5 more results
16.5%Etanercept Monotherapy
NCT02376790 · Phase 3 · monotherapy
35.5%
NCT00127842 · Phase 4 · registry result, not featured evidence
4%BIW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
2.9%QW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
—
NCT02986139 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—Etanercept + Methotrexatea
NCT02376790 · Phase 3 · combination
show 5 more results
—Etanercept Monotherapy
NCT02376790 · Phase 3 · monotherapy
13.6%
NCT00127842 · Phase 4 · registry result, not featured evidence
1.6%BIW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
1.9%QW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
—
NCT02986139 · Phase 3 · registry result, not featured evidence
Serious AEs
6%Etanercept + Methotrexatea
NCT02376790 · Phase 3 · combination
show 5 more results
6.7%Etanercept Monotherapy
NCT02376790 · Phase 3 · monotherapy
12.7%
NCT00127842 · Phase 4 · registry result, not featured evidence
—BIW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
—QW/QW
NCT00245960 · Phase 4 · registry result, not featured evidence
0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
nausea 14.4%
nasopharyngitis 9.5%
upper respiratory tract infection 8.1%
NCT02376790 · Phase 3 · combination
show 5 more results
nasopharyngitis 7.4%
nausea 6.4%
upper respiratory tract infection 6.4%
NCT02376790 · Phase 3 · monotherapy
nasopharyngitis 18.2%
upper respiratory tract infection 13.6%
injection site reaction 11.8%
NCT00127842 · Phase 4 · registry result, not featured evidence
BIW/QW
upper respiratory infection 13.2%
skin and appendages general disorders 11.9%
digestive general disorders 10%
NCT00245960 · Phase 4 · registry result, not featured evidence
QW/QW
skin and appendages general disorders 11%
digestive general disorders 9.9%
upper respiratory infection 9.7%
NCT00245960 · Phase 4 · registry result, not featured evidence
hypoaesthesia 1.9%
pain in extremity 1.9%
cellulitis 0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

etanercept

ACR20 60.9% (n=284) vs 50.7% (n=284) Methotrexate @ 24wk
responder rate · % of participants
NCT02376790 · Phase 3 · monotherapy
show 15 more results
65% (n=283) vs 50.7% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
44.3% (n=284) vs 25% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · monotherapy
46.4% (n=283) vs 25% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · combination
60.2% (n=284) vs 46.5% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · monotherapy
60.8% (n=283) vs 46.5% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · combination
65.5% (n=284) vs 46.8% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · monotherapy
70.3% (n=283) vs 46.8% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · combination
69.5% (n=284) vs 58.5% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · monotherapy
71.8% (n=283) vs 58.5% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · combination
67.6% (n=284) vs 56.9% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · monotherapy
71.9% (n=283) vs 56.9% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
77% (n=284) vs 66.3% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · monotherapy
74.2% (n=283) vs 66.3% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · combination
83.1% (n=284) vs 70.7% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · monotherapy
80.4% (n=283) vs 70.7% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · combination
MDA 35.9% (n=284) vs 22.9% (n=284) Methotrexate @ 24wk
responder rate · % of participants
NCT02376790 · Phase 3 · monotherapy
show 13 more results
35.7% (n=283) vs 22.9% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
11.1% (n=284) vs 5.7% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · monotherapy
12.6% (n=283) vs 5.7% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · combination
9.4% (n=284) vs 3% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · monotherapy
7.4% (n=283) vs 3% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · combination
29.9% (n=284) vs 11.6% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · monotherapy
29.1% (n=283) vs 11.6% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · combination
39.5% (n=284) vs 25.7% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · monotherapy
39.1% (n=283) vs 25.7% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
43.5% (n=284) vs 30.3% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · monotherapy
46.7% (n=283) vs 30.3% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · combination
51.3% (n=284) vs 35.8% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · monotherapy
53.2% (n=283) vs 35.8% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · combination
ACR50 16.5% (n=284) vs 6% (n=284) Methotrexate @ 4wk
responder rate · % of participants
NCT02376790 · Phase 3 · monotherapy
show 13 more results
18.8% (n=283) vs 6% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · combination
31.3% (n=284) vs 15.1% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · monotherapy
30.1% (n=283) vs 15.1% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · combination
40.4% (n=284) vs 16.9% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · monotherapy
39.2% (n=283) vs 16.9% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · combination
43.8% (n=284) vs 29.2% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · monotherapy
43.4% (n=283) vs 29.2% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · combination
44.4% (n=284) vs 30.6% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · monotherapy
45.7% (n=283) vs 30.6% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
57.3% (n=284) vs 41.8% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · monotherapy
56% (n=283) vs 41.8% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · combination
63% (n=284) vs 49.3% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · monotherapy
60.2% (n=283) vs 49.3% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · combination
ACR70 3.6% (n=284) vs 2.8% (n=284) Methotrexate @ 4wk
responder rate · % of participants
NCT02376790 · Phase 3 · monotherapy
show 13 more results
5.1% (n=283) vs 2.8% (n=284) Methotrexate @ 4wk
NCT02376790 · Phase 3 · combination
15.2% (n=284) vs 4.4% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · monotherapy
14.5% (n=283) vs 4.4% (n=284) Methotrexate @ 8wk
NCT02376790 · Phase 3 · combination
24.3% (n=284) vs 5.2% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · monotherapy
22.3% (n=283) vs 5.2% (n=284) Methotrexate @ 12wk
NCT02376790 · Phase 3 · combination
24.2% (n=284) vs 10.7% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · monotherapy
25.5% (n=283) vs 10.7% (n=284) Methotrexate @ 16wk
NCT02376790 · Phase 3 · combination
29.2% (n=284) vs 13.8% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · monotherapy
27.7% (n=283) vs 13.8% (n=284) Methotrexate @ 24wk
NCT02376790 · Phase 3 · combination
38.5% (n=284) vs 19.6% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · monotherapy
33.5% (n=283) vs 19.6% (n=284) Methotrexate @ 36wk
NCT02376790 · Phase 3 · combination
39.7% (n=284) vs 25.2% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · monotherapy
39.7% (n=283) vs 25.2% (n=284) Methotrexate @ 48wk
NCT02376790 · Phase 3 · combination
Tender Joint Count -6.4 vs -5.7 Methotrexate tender joints @ 4wk
absolute change · tender joints
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-7.4 vs -5.7 Methotrexate tender joints @ 4wk
NCT02376790 · Phase 3 · combination
-8.9 vs -7.8 Methotrexate tender joints @ 8wk
NCT02376790 · Phase 3 · monotherapy
-9.4 vs -7.8 Methotrexate tender joints @ 8wk
NCT02376790 · Phase 3 · combination
-9.8 vs -9.7 Methotrexate tender joints @ 12wk
NCT02376790 · Phase 3 · monotherapy
-10.8 vs -9.7 Methotrexate tender joints @ 12wk
NCT02376790 · Phase 3 · combination
-10.9 vs -10 Methotrexate tender joints @ 16wk
NCT02376790 · Phase 3 · monotherapy
-11.9 vs -10 Methotrexate tender joints @ 16wk
NCT02376790 · Phase 3 · combination
-10.9 vs -10.8 Methotrexate tender joints @ 24wk
NCT02376790 · Phase 3 · monotherapy
-11 vs -10.8 Methotrexate tender joints @ 24wk
NCT02376790 · Phase 3 · combination
-12.7 vs -13.5 Methotrexate tender joints @ 36wk
NCT02376790 · Phase 3 · monotherapy
-12.9 vs -13.5 Methotrexate tender joints @ 36wk
NCT02376790 · Phase 3 · combination
-13.9 vs -14.5 Methotrexate tender joints @ 48wk
NCT02376790 · Phase 3 · monotherapy
-12.9 vs -14.5 Methotrexate tender joints @ 48wk
NCT02376790 · Phase 3 · combination
Swollen Joint Count -4.8 vs -4.1 Methotrexate swollen joints @ 4wk
absolute change · swollen joints
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-4.7 vs -4.1 Methotrexate swollen joints @ 4wk
NCT02376790 · Phase 3 · combination
-6.2 vs -5.4 Methotrexate swollen joints @ 8wk
NCT02376790 · Phase 3 · monotherapy
-6.5 vs -5.4 Methotrexate swollen joints @ 8wk
NCT02376790 · Phase 3 · combination
-6.8 vs -6.6 Methotrexate swollen joints @ 12wk
NCT02376790 · Phase 3 · monotherapy
-7.2 vs -6.6 Methotrexate swollen joints @ 12wk
NCT02376790 · Phase 3 · combination
-7.3 vs -7 Methotrexate swollen joints @ 16wk
NCT02376790 · Phase 3 · monotherapy
-7.8 vs -7 Methotrexate swollen joints @ 16wk
NCT02376790 · Phase 3 · combination
-7.6 vs -7 Methotrexate swollen joints @ 24wk
NCT02376790 · Phase 3 · monotherapy
-7.7 vs -7 Methotrexate swollen joints @ 24wk
NCT02376790 · Phase 3 · combination
-9 vs -9.2 Methotrexate swollen joints @ 36wk
NCT02376790 · Phase 3 · monotherapy
-8.4 vs -9.2 Methotrexate swollen joints @ 36wk
NCT02376790 · Phase 3 · combination
-9.2 vs -9.6 Methotrexate swollen joints @ 48wk
NCT02376790 · Phase 3 · monotherapy
-8.7 vs -9.6 Methotrexate swollen joints @ 48wk
NCT02376790 · Phase 3 · combination
Physician Global Assessment -23.1 vs -16.8 Methotrexate mm @ 4wk
absolute change · mm
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-22.8 vs -16.8 Methotrexate mm @ 4wk
NCT02376790 · Phase 3 · combination
-29.7 vs -25 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · monotherapy
-30.4 vs -25 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · combination
-32.7 vs -26.8 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · monotherapy
-33.9 vs -26.8 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · combination
-34.9 vs -30.3 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · monotherapy
-36.2 vs -30.3 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · combination
-35.7 vs -29.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · monotherapy
-35.8 vs -29.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · combination
-42.8 vs -37.1 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · monotherapy
-39.9 vs -37.1 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · combination
-43.8 vs -41.4 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · monotherapy
-41.5 vs -41.4 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · combination
Patient Global Assessment -21.9 vs -11 Methotrexate mm @ 4wk
absolute change · mm
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-21 vs -11 Methotrexate mm @ 4wk
NCT02376790 · Phase 3 · combination
-27.3 vs -15.6 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · monotherapy
-26.4 vs -15.6 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · combination
-29.9 vs -18.6 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · monotherapy
-28 vs -18.6 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · combination
-30.9 vs -22.7 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · monotherapy
-29.3 vs -22.7 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · combination
-32.3 vs -23 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · monotherapy
-29.6 vs -23 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · combination
-36.4 vs -26 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · monotherapy
-32.4 vs -26 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · combination
-38.8 vs -28.9 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · monotherapy
-33.3 vs -28.9 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · combination
Patient Assessment of Arthritis Pain -18.4 vs -8.9 Methotrexate mm @ 4wk
absolute change · mm
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-18.5 vs -8.9 Methotrexate mm @ 4wk
NCT02376790 · Phase 3 · combination
-23.5 vs -14.5 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · monotherapy
-24 vs -14.5 Methotrexate mm @ 8wk
NCT02376790 · Phase 3 · combination
-24.1 vs -16 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · monotherapy
-24.9 vs -16 Methotrexate mm @ 12wk
NCT02376790 · Phase 3 · combination
-25.9 vs -20.9 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · monotherapy
-25.6 vs -20.9 Methotrexate mm @ 16wk
NCT02376790 · Phase 3 · combination
-26.4 vs -20.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · monotherapy
-26.9 vs -20.6 Methotrexate mm @ 24wk
NCT02376790 · Phase 3 · combination
-31.5 vs -23.9 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · monotherapy
-28.8 vs -23.9 Methotrexate mm @ 36wk
NCT02376790 · Phase 3 · combination
-32.5 vs -27.2 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · monotherapy
-31.1 vs -27.2 Methotrexate mm @ 48wk
NCT02376790 · Phase 3 · combination
HAQ-DI -0.266 vs -0.188 Methotrexate score @ 4wk
absolute change · score
NCT02376790 · Phase 3 · monotherapy
show 15 more results
-0.306 vs -0.188 Methotrexate score @ 4wk
NCT02376790 · Phase 3 · combination
-0.365 vs -0.277 Methotrexate score @ 8wk
NCT02376790 · Phase 3 · monotherapy
-0.403 vs -0.277 Methotrexate score @ 8wk
NCT02376790 · Phase 3 · combination
-0.404 vs -0.31 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · monotherapy
-0.45 vs -0.31 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · combination
-0.454 vs -0.378 Methotrexate score @ 16wk
NCT02376790 · Phase 3 · monotherapy
-0.483 vs -0.378 Methotrexate score @ 16wk
NCT02376790 · Phase 3 · combination
-0.444 vs -0.412 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · monotherapy
-0.468 vs -0.412 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · combination
-0.496 vs -0.452 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · monotherapy
-0.548 vs -0.452 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · combination
-0.557 vs -0.526 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · monotherapy
-0.554 vs -0.526 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · combination
-0.444 vs -0.412 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · monotherapy
-0.468 vs -0.412 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · combination
CRP Change -5.91 vs -0.93 Methotrexate mg @ 4wk
absolute change · mg
NCT02376790 · Phase 3 · monotherapy
show 13 more results
-5.49 vs -0.93 Methotrexate mg @ 4wk
NCT02376790 · Phase 3 · combination
-7.51 vs -2.31 Methotrexate mg @ 8wk
NCT02376790 · Phase 3 · monotherapy
-5.19 vs -2.31 Methotrexate mg @ 8wk
NCT02376790 · Phase 3 · combination
-7.38 vs -3.36 Methotrexate mg @ 12wk
NCT02376790 · Phase 3 · monotherapy
-5.71 vs -3.36 Methotrexate mg @ 12wk
NCT02376790 · Phase 3 · combination
-7.4 vs -2.81 Methotrexate mg @ 16wk
NCT02376790 · Phase 3 · monotherapy
-5.59 vs -2.81 Methotrexate mg @ 16wk
NCT02376790 · Phase 3 · combination
-6.91 vs -2.6 Methotrexate mg @ 24wk
NCT02376790 · Phase 3 · monotherapy
-5.82 vs -2.6 Methotrexate mg @ 24wk
NCT02376790 · Phase 3 · combination
-7.36 vs -4.16 Methotrexate mg @ 36wk
NCT02376790 · Phase 3 · monotherapy
-5.82 vs -4.16 Methotrexate mg @ 36wk
NCT02376790 · Phase 3 · combination
-7.45 vs -4.88 Methotrexate mg @ 48wk
NCT02376790 · Phase 3 · monotherapy
-5.81 vs -4.88 Methotrexate mg @ 48wk
NCT02376790 · Phase 3 · combination
PSAAD -2.32 vs -1.63 Methotrexate score @ 12wk
absolute change · score
NCT02376790 · Phase 3 · monotherapy
show 7 more results
-2.37 vs -1.63 Methotrexate score @ 12wk
NCT02376790 · Phase 3 · combination
-2.64 vs -1.98 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · monotherapy
-2.63 vs -1.98 Methotrexate score @ 24wk
NCT02376790 · Phase 3 · combination
-3.1 vs -2.46 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · monotherapy
-2.95 vs -2.46 Methotrexate score @ 36wk
NCT02376790 · Phase 3 · combination
-3.23 vs -2.7 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · monotherapy
-3.1 vs -2.7 Methotrexate score @ 48wk
NCT02376790 · Phase 3 · combination

+ 23 further endpoints in the CSV export.

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab-aacf (Idacio)

Marketed by Fresenius SE & Co. KGaA

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02660580 · Phase 3 · completed

This was a randomized, double-blind, active-controlled phase 3 trial with 443 participants, using the clinical psoriasis endpoint PASI 75 at Week 16. MSB11022 met the prespecified equivalence criterion versus EU-Humira: the 95% confidence interval for the treatment difference was -7.82% to 4.07%, within the predefined -18% to 18% range.

No aligned efficacy figure on record for this race.

etanercept · Enbrel

Marketed by Amgen and partners

Approved in Psoriasisfusion protein
Weak signal

NCT00111436 · Phase 3 · completed

Participants in this study had already been randomized in an earlier controlled trial and continued on etanercept here as an open-label extension to gather longer-term safety data, rather than as a fresh randomized comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Subject incidence of adverse events, including infectious episodes" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Subject incidence of adverse events, including infectious episodes (72 weeks); Changes from baseline in laboratory values (72 weeks): Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases. (not_applicable)

Result source: NCT00111436

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aacf (Idacio)etanercept
PASI 75—Not reported57% vs 11%+46 vs placebowk 12 · n 106NCT00078819
2 other results
  • 48.2% vs 11.9% 50 mg SC QW · wk 16 · n 83 · Phase 3 · secondary NCT01690299
  • 63.3% vs 26.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200
PASI 90—Not reported27% vs 7%+20 vs placebowk 12 · n 106NCT00078819
PASI 100—Not reported—Not posted · NCT00111449
sPGA 0/1—Not reported28.9% vs 3.6%+25.3 vs placebo50 mg SC QW · wk 16 · n 83NCT01690299
2 other results
  • 53% vs 13% wk 12 · n 106 · Phase 3 · secondary NCT00078819
  • 53.3% vs 5.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200
DLQI, change—Not reported-7.8 vs -3.9−3.9 vs placebo50 mg SC QW · wk 16 · n 80NCT01690299

PASI 75

adalimumab-aacf (Idacio)
—Not reported
etanercept
57% vs 11%+46 vs placebowk 12 · n 106NCT00078819
2 other results
  • 48.2% vs 11.9% 50 mg SC QW · wk 16 · n 83 · Phase 3 · secondary NCT01690299
  • 63.3% vs 26.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200

PASI 90

adalimumab-aacf (Idacio)
—Not reported
etanercept
27% vs 7%+20 vs placebowk 12 · n 106NCT00078819

PASI 100

adalimumab-aacf (Idacio)
—Not reported
etanercept
—Not posted · NCT00111449

sPGA 0/1

adalimumab-aacf (Idacio)
—Not reported
etanercept
28.9% vs 3.6%+25.3 vs placebo50 mg SC QW · wk 16 · n 83NCT01690299
2 other results
  • 53% vs 13% wk 12 · n 106 · Phase 3 · secondary NCT00078819
  • 53.3% vs 5.3% wk 12 · n 30 · Phase 3 · secondary NCT03073200

DLQI, change

adalimumab-aacf (Idacio)
—Not reported
etanercept
-7.8 vs -3.9−3.9 vs placebo50 mg SC QW · wk 16 · n 80NCT01690299
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-aacf (Idacio): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-aacf (Idacio): 0 of 4 rows · etanercept: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricetanercept
Dropout rate
—0.8 mg/kg QWa
NCT00078819 · Phase 3
show 35 more results
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
0.9%Etanercept
NCT00078819 · Phase 3
17.5%
NCT02749370 · Phase 4 · registry result, not featured evidence
16%
NCT01971346 · Phase 4 · registry result, not featured evidence
18.9%
NCT02274792 · Phase 4 · registry result, not featured evidence
16.3%
NCT00992394 · Phase 4 · registry result, not featured evidence
0%
NCT01053819 · Phase 4 · registry result, not featured evidence
5.1%Part 1 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept and nbUVB
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
6.5%50 mg BIW/QW
NCT00791765 · Phase 4 · registry result, not featured evidence
27.6%
NCT00332332 · Phase 4 · registry result, not featured evidence
8.8%50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
7.3%50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
34.5%
NCT00581555 · Phase 4 · registry result, not featured evidence
14.7%Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
18.4%Twice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
27.7%Continuous
NCT00195507 · Phase 4 · registry result, not featured evidence
32.5%Intermittent
NCT00195507 · Phase 4 · registry result, not featured evidence
0%
NCT03073200 · Phase 3 · registry result, not featured evidence
77.5%
NCT00141921 · Phase 3 · registry result, not featured evidence
2.4%50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
—50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
5.6%50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
—Etanercept Monotherapy
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
14.9%Etanercept + Clobetasol Propionate
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
14.8%Etanercept Monotherapy
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
7.2%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
9.3%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
0%50 mg twice weekly
NCT00585650 · Phase 1/2 · registry result, not featured evidence
33.3%
NCT01170715 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—0.8 mg/kg QWa
NCT00078819 · Phase 3
show 35 more results
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
—0.8 mg/kg QW
NCT00078819 · Phase 3
0.9%Etanercept
NCT00078819 · Phase 3
—
NCT02749370 · Phase 4 · registry result, not featured evidence
—
NCT01971346 · Phase 4 · registry result, not featured evidence
—
NCT02274792 · Phase 4 · registry result, not featured evidence
5.8%
NCT00992394 · Phase 4 · registry result, not featured evidence
—
NCT01053819 · Phase 4 · registry result, not featured evidence
—Part 1 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
—Part 2 - Etanercept and nbUVB
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
1.6%50 mg BIW/QW
NCT00791765 · Phase 4 · registry result, not featured evidence
5.3%
NCT00332332 · Phase 4 · registry result, not featured evidence
4.4%50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
2.2%50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
5.2%
NCT00581555 · Phase 4 · registry result, not featured evidence
2.9%Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
5.3%Twice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
6.7%Continuous
NCT00195507 · Phase 4 · registry result, not featured evidence
3.6%Intermittent
NCT00195507 · Phase 4 · registry result, not featured evidence
—
NCT03073200 · Phase 3 · registry result, not featured evidence
2.7%
NCT00141921 · Phase 3 · registry result, not featured evidence
1.2%50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
—50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
0%50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
—Etanercept Monotherapy
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
2%Etanercept + Clobetasol Propionate
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
1.3%Etanercept Monotherapy
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
2.4%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
6.5%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
—50 mg twice weekly
NCT00585650 · Phase 1/2 · registry result, not featured evidence
—
NCT01170715 · Phase na · registry result, not featured evidence
Serious AEs
0%0.8 mg/kg QWa
NCT00078819 · Phase 3
show 35 more results
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
0%0.8 mg/kg QW
NCT00078819 · Phase 3
—Etanercept
NCT00078819 · Phase 3
2.5%
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2%
NCT01971346 · Phase 4 · registry result, not featured evidence
3.8%
NCT02274792 · Phase 4 · registry result, not featured evidence
4.8%
NCT00992394 · Phase 4 · registry result, not featured evidence
0%
NCT01053819 · Phase 4 · registry result, not featured evidence
1%Part 1 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
5.3%Part 2 - Etanercept
NCT00640393 · Phase 4 · registry result, not featured evidence
0%Part 2 - Etanercept and nbUVB
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
3.4%50 mg BIW/QW
NCT00791765 · Phase 4 · registry result, not featured evidence
5.2%
NCT00332332 · Phase 4 · registry result, not featured evidence
2.2%50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
2.9%50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
3.4%
NCT00581555 · Phase 4 · registry result, not featured evidence
0%Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
5.3%Twice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
—Continuous
NCT00195507 · Phase 4 · registry result, not featured evidence
—Intermittent
NCT00195507 · Phase 4 · registry result, not featured evidence
3.3%
NCT03073200 · Phase 3 · registry result, not featured evidence
3.9%
NCT00141921 · Phase 3 · registry result, not featured evidence
—50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
2.4%50 mg SC QW
NCT01690299 · Phase 3 · registry result, not featured evidence
—50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
2.3%Etanercept Monotherapy
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
2.4%Etanercept + Clobetasol Propionate
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
2%Etanercept Monotherapy
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
2.9%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
2.4%50 mg
NCT00482170 · Phase 3 · registry result, not featured evidence
0%50 mg twice weekly
NCT00585650 · Phase 1/2 · registry result, not featured evidence
9.5%
NCT01170715 · Phase na · registry result, not featured evidence
Most frequent reported AEs
0.8 mg/kg QWa
upper respiratory tract infection 12.5% (placebo 11.4%)
skin papilloma 6.3% (placebo 0%)
acne 3.1% (placebo 0%)
NCT00078819 · Phase 3
show 31 more results
0.8 mg/kg QW
upper respiratory tract infection 17% (placebo 11.4%)
headache 13.2% (placebo 12.4%)
influenza 7.5% (placebo 1.9%)
NCT00078819 · Phase 3
0.8 mg/kg QW
upper respiratory tract infection 42.4% (placebo 11.4%)
headache 20.3% (placebo 12.4%)
nasopharyngitis 20.3% (placebo 8.6%)
NCT00078819 · Phase 3
0.8 mg/kg QW
upper respiratory tract infection 30.8% (placebo 11.4%)
headache 20.2% (placebo 12.4%)
nasopharyngitis 18.8% (placebo 8.6%)
NCT00078819 · Phase 3
0.8 mg/kg QW
upper respiratory tract infection 25% (placebo 11.4%)
abdominal pain 8.3% (placebo 0%)
body tinea 8.3% (placebo 0%)
NCT00078819 · Phase 3
0.8 mg/kg QW
nasopharyngitis 10.3% (placebo 8.6%)
headache 8.8% (placebo 12.4%)
acne 2.9% (placebo 0%)
NCT00078819 · Phase 3
back pain 2.5%
exostosis 2.5%
injection related reaction 2.5%
NCT02749370 · Phase 4 · registry result, not featured evidence
nasal congestion 8.7%
gi distress 6.5%
injection site reaction 6.5%
NCT01971346 · Phase 4 · registry result, not featured evidence
injection site reaction 7.6%
psoriasis 6.1%
headache 5.3%
NCT02274792 · Phase 4 · registry result, not featured evidence
nasopharyngitis 26.2%
bronchitis 10.7%
arthralgia 7.1%
NCT00992394 · Phase 4 · registry result, not featured evidence
common cold 9.1%
injection site reaction 4%
upper respiratory tract infection 4%
NCT00640393 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 15.8%
common cold 13.2%
injection site reaction 0%
NCT00640393 · Phase 4 · registry result, not featured evidence
common cold 5.4%
upper respiratory tract infection 2.7%
injection site reaction 0%
NCT00640393 · Phase 4 · registry result, not featured evidence · combination
50 mg BIW/QW
nasopharyngitis 8.5% (placebo 8.1%)
upper respiratory tract infection 8.5% (placebo 14.5%)
arthralgia 6.8% (placebo 3.2%)
NCT00791765 · Phase 4 · registry result, not featured evidence
nasopharyngitis 7.8%
headache 7%
upper respiratory tract infection 7%
NCT00332332 · Phase 4 · registry result, not featured evidence
50 mg BW/QW
headache 11%
nasopharyngitis 10.3%
upper respiratory tract infection 6.6%
NCT00663052 · Phase 4 · registry result, not featured evidence
50 mg QW/QW
nasopharyngitis 16.1%
headache 10.9%
diarrhoea 7.3%
NCT00663052 · Phase 4 · registry result, not featured evidence
headache 29.3% (placebo 33.9%)
nasopharyngitis 19% (placebo 21%)
hypertension 15.5% (placebo 14.5%)
NCT00581555 · Phase 4 · registry result, not featured evidence
Once Weekly
nasopharyngitis 11.8%
headache nos 8.8%
alopecia areata 2.9%
NCT00581100 · Phase 4 · registry result, not featured evidence
Twice, Then Once Weekly
headache nos 10.5%
nasopharyngitis 10.5%
dermatitis allergic 5.3%
NCT00581100 · Phase 4 · registry result, not featured evidence
upper respiratory infection 17.9%
headache 17.6%
nervous 13.4%
NCT00195507 · Phase 4 · registry result, not featured evidence
upper respiratory infection 17.4%
headache 12.9%
arthralgia 11%
NCT00195507 · Phase 4 · registry result, not featured evidence
influenza 6.7% (placebo 0%)
pharyngitis 6.7% (placebo 0%)
bronchitis 3.3% (placebo 0%)
NCT03073200 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 37.6%
nasopharyngitis 26%
headache 21.5%
NCT00141921 · Phase 3 · registry result, not featured evidence
50 mg SC QW
nasopharyngitis 9.6% (placebo 9.5%)
headache 6% (placebo 3.6%)
cough 4.8% (placebo 3.6%)
NCT01690299 · Phase 3 · registry result, not featured evidence
nasopharyngitis 13.6%
headache 10.7%
injection site reaction 9%
NCT01313221 · Phase 3 · registry result, not featured evidence · monotherapy
nasopharyngitis 8.3%
upper respiratory tract infection 6.9%
sinusitis 6.3%
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 11.6%
nasopharyngitis 8.6%
headache 7.3%
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
50 mg
nasopharyngitis 11.6%
injection site reaction 8.7%
headache 6.3%
NCT00482170 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 12.8%
injection site erythema 8.1%
injection site reaction 8.1%
NCT00482170 · Phase 3 · registry result, not featured evidence
50 mg twice weekly
upper respiratory infection 37.5% (placebo 33.3%)
NCT00585650 · Phase 1/2 · registry result, not featured evidence
upper respiratory infection 28.6%
fatigue 9.5%
rash 9.5%
NCT01170715 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

etanercept

PASI 75 48.2% (n=83) vs 11.9% (n=84) placebo @ 16wk50 mg SC QW
responder rate · % of participants
NCT01690299 · Phase 3 · registry result, not featured evidence
show 2 more results
57% (n=106) vs 11% (n=105) placebo @ 12wk
NCT00078819 · Phase 3
63.3% (n=30) vs 26.3% (n=19) placebo @ 12wk
NCT03073200 · Phase 3 · registry result, not featured evidence
PASI 50 83.1% (n=83) vs 33.3% (n=84) placebo @ 16wk50 mg SC QW
responder rate · % of participants
NCT01690299 · Phase 3 · registry result, not featured evidence
show 1 more result
75% (n=106) vs 23% (n=105) placebo @ 12wk
NCT00078819 · Phase 3
sPGA 0/1 28.9% (n=83) vs 3.6% (n=84) placebo @ 16wk50 mg SC QW
responder rate · % of participants
NCT01690299 · Phase 3 · registry result, not featured evidence
show 2 more results
53% (n=106) vs 13% (n=105) placebo @ 12wk
NCT00078819 · Phase 3
53.3% (n=30) vs 5.3% (n=19) placebo @ 12wk
NCT03073200 · Phase 3 · registry result, not featured evidence
CDLQI 52.3% (n=100) vs 17.5% (n=102) placebo @ 12wk
absolute change · percentage points
NCT00078819 · Phase 3
PASI 90 27% (n=106) vs 7% (n=105) placebo @ 12wk
responder rate · % of participants
NCT00078819 · Phase 3
PASI 75 78.2% (n=133) @ 24wk50 mg BW/QW
responder rate · % of participants
No placebo or comparator arm
NCT00663052 · Phase 4 · registry result, not featured evidence
show 52 more results
59.9% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
1.5% (n=133) @ 2wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
0% (n=137) @ 2wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
6% (n=133) @ 4wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
4.4% (n=137) @ 4wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
35.3% (n=133) @ 8wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
21.9% (n=137) @ 8wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
62.4% (n=133) @ 12wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
37.2% (n=137) @ 12wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
72.9% (n=133) @ 16wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
51.1% (n=137) @ 16wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
78.2% (n=133) @ 20wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
58.4% (n=137) @ 20wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
78.2% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
59.9% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
52.1% (n=143) @ 12wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
58.7% (n=143) @ 16wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
58.9% (n=143) @ 20wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
60.3% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
41.6% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
6.6% (n=77) @ 4wk
NCT02749370 · Phase 4 · registry result, not featured evidence
23.4% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
41.6% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
42.9% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
42.9% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
45.5% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
48.6% (n=37) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
34.2% (n=38) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
40.5% (n=37) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 15 Participants as posted
31.6% (n=38) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 12 Participants as posted
62.2% (n=37) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted
44.7% (n=38) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
51.4% (n=37) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
44.7% (n=38) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
13.1% (n=99) @ 4wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
50.5% (n=99) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 50 Participants as posted
42.9% (n=7) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
37.9% (n=29) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
85.7% (n=7) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
41.4% (n=29) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 12 Participants as posted
100% (n=7) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
55.2% (n=29) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 16 Participants as posted
100% (n=7) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
55.2% (n=29) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 16 Participants as posted
51.52% (n=36) @ 12wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
58.06% (n=33) @ 12wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
77.14% (n=36) @ 24wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
62.5% (n=33) @ 24wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
48.3% (n=297) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
65.2% (n=295) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
63.6% (n=297) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
69.3% (n=295) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
PASI 50 9% (n=133) @ 2wk50 mg BW/QW
responder rate · % of participants
No placebo or comparator arm
NCT00663052 · Phase 4 · registry result, not featured evidence
show 29 more results
5.9% (n=137) @ 2wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
38.3% (n=133) @ 4wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
20.4% (n=137) @ 4wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
71.4% (n=133) @ 8wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
51.8% (n=137) @ 8wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
88% (n=133) @ 12wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
67.9% (n=137) @ 12wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
92.5% (n=133) @ 16wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
78.1% (n=137) @ 16wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
93.2% (n=133) @ 20wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
82.5% (n=137) @ 20wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
92.5% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
81% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
75.4% (n=143) @ 12wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
86.2% (n=143) @ 16wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
86.5% (n=143) @ 20wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
88.7% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
23.7% (n=77) @ 4wk
NCT02749370 · Phase 4 · registry result, not featured evidence
50.6% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
70.1% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
68.8% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
74% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
62.3% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
37.4% (n=99) @ 4wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 37 Participants as posted
82.8% (n=99) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 82 Participants as posted
90.91% (n=36) @ 12wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
87.1% (n=33) @ 12wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
85.71% (n=36) @ 24wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
84.38% (n=33) @ 24wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
PASI 90 0% (n=133) @ 2wk50 mg BW/QW
responder rate · % of participants
No placebo or comparator arm
NCT00663052 · Phase 4 · registry result, not featured evidence
show 43 more results
0% (n=137) @ 2wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
0.8% (n=133) @ 4wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
0.7% (n=137) @ 4wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
9.8% (n=133) @ 8wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
5.8% (n=137) @ 8wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
29.3% (n=133) @ 12wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
10.9% (n=137) @ 12wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
42.9% (n=133) @ 16wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
25.5% (n=137) @ 16wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
45.1% (n=133) @ 20wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
29.2% (n=137) @ 20wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
49.6% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
32.8% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
12.7% (n=143) @ 12wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
22.5% (n=143) @ 16wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
22% (n=143) @ 20wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
27% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
1.3% (n=77) @ 4wk
NCT02749370 · Phase 4 · registry result, not featured evidence
6.5% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
13% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
16.9% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
23.4% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
22.1% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
0% (n=37) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=38) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
8.1% (n=37) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
2.6% (n=38) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 1 Participants as posted
13.5% (n=37) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
13.2% (n=38) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
16.2% (n=37) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
15.8% (n=38) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
3% (n=99) @ 4wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 3 Participants as posted
17.2% (n=99) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 17 Participants as posted
0% (n=7) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=29) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 0 Participants as posted
42.9% (n=7) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
3.4% (n=29) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 1 Participants as posted
42.9% (n=7) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
17.2% (n=29) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 5 Participants as posted
42.9% (n=7) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
20.7% (n=29) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
19.4% (n=297) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
29.7% (n=295) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
PASI 0.86% (n=140) @ 24wk50 mg QW + topical
percent change · % of baseline
No placebo or comparator arm
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
show 12 more results
65.48% (n=143) @ 12wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
72.67% (n=143) @ 16wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
73.25% (n=143) @ 20wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
72.56% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
22.03% (n=77) @ 4wk
NCT02749370 · Phase 4 · registry result, not featured evidence
43.51% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
55.47% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
57.41% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
60.42% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
57.67% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
68.18% (n=297) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
76.46% (n=295) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
sPGA 0/1 0.8% (n=133) @ 2wk50 mg BW/QW
responder rate · % of participants
No placebo or comparator arm
NCT00663052 · Phase 4 · registry result, not featured evidence
show 45 more results
2.2% (n=137) @ 2wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
12.8% (n=133) @ 4wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
6.6% (n=137) @ 4wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
33.8% (n=133) @ 8wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
18.2% (n=137) @ 8wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
54.9% (n=133) @ 12wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
32.8% (n=137) @ 12wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
60.9% (n=133) @ 16wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
47.4% (n=137) @ 16wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
65.4% (n=133) @ 20wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
50.4% (n=137) @ 20wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
69.9% (n=133) @ 24wk50 mg BW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
50.4% (n=137) @ 24wk50 mg QW/QW
NCT00663052 · Phase 4 · registry result, not featured evidence
45.8% (n=143) @ 12wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
50.4% (n=143) @ 16wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
48.9% (n=143) @ 20wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
45.4% (n=143) @ 24wk50 mg QW + topical
NCT01313221 · Phase 3 · registry result, not featured evidence · combination
3.9% (n=77) @ 4wk
NCT02749370 · Phase 4 · registry result, not featured evidence
15.6% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
23.4% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
28.6% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
29.9% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
33.8% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
29.7% (n=37) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 11 Participants as posted
28.9% (n=38) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
35.1% (n=37) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 13 Participants as posted
21.1% (n=38) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 8 Participants as posted
35.1% (n=37) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 13 Participants as posted
28.9% (n=38) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
32.4% (n=37) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 12 Participants as posted
34.2% (n=38) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 13 Participants as posted
57.1% (n=7) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted
31% (n=29) @ 12wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 9 Participants as posted
71.4% (n=7) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
20.7% (n=29) @ 16wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 6 Participants as posted
85.7% (n=7) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted
31% (n=29) @ 20wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 9 Participants as posted
100% (n=7) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
37.9% (n=29) @ 24wk*
NCT00640393 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted
68.57% (n=35) @ 24wkTwice, Then Once Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
75% (n=32) @ 24wkOnce Weekly
NCT00581100 · Phase 4 · registry result, not featured evidence
47.3% (n=297) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
63.1% (n=295) @ 12wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
54.8% (n=297) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · monotherapy
61.7% (n=295) @ 24wk
NCT01235442 · Phase 3 · registry result, not featured evidence · combination
sPGA Leq2 21.1% (n=77) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT02749370 · Phase 4 · registry result, not featured evidence
show 5 more results
55.8% (n=77) @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
62.3% (n=77) @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
59.7% (n=77) @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
55.8% (n=77) @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
57.1% (n=77) @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence
sPGA 2.9 score @ 4wk
absolute value · score
No placebo or comparator arm
NCT02749370 · Phase 4 · registry result, not featured evidence
show 5 more results
2.4 score @ 8wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 12wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 16wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 20wk
NCT02749370 · Phase 4 · registry result, not featured evidence
2.2 score @ 24wk
NCT02749370 · Phase 4 · registry result, not featured evidence

+ 51 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-aacf (Idacio)

Marketed by Fresenius SE & Co. KGaA

Approved in Rheumatoid Arthritismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

etanercept · Enbrel

Marketed by Amgen and partners

Approved in Rheumatoid Arthritisfusion protein
Partial signal

NCT03780959 · Phase 2/3 · completed

After 90 days of open-label etanercept, 51 responding children were randomized to continue etanercept or receive placebo in a double-blind comparison. The clinical primary endpoint, disease flare, was met in favor of etanercept (28% vs 81% with placebo; p=0.0030), but the randomized sample was small, limiting the strength of the evidence.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

Reported efficacy

Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81% (met)

Result source: NCT03780959

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aacf (Idacio)etanercept
ACR20—Not reported78.6% vs 62.5%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
63 other results
  • 79.7% vs 59.1% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 59.7% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 80.8% vs 58% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 56.3% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 78.6% vs 58.5% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 51.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 48.3% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 68.7% vs 43.2% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 56.9% vs 27.3% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 49.4% vs 16.1% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 75.9% vs 62.5% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 76.4% vs 59.1% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 78.5% vs 59.7% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 79.1% vs 58% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 77% vs 56.3% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 75.4% vs 58.5% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 73.8% vs 51.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 70.2% vs 48.3% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 68.1% vs 43.2% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 55.5% vs 27.3% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 54% vs 16.1% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 75.5% vs 48.7% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 79.5% vs 46.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 78% vs 47.2% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 48.7% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 75% vs 50.3% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 77% vs 50.3% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 76.9% vs 61.2% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 86.5% vs 88.3% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 74.6% vs 48.7% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 77.6% vs 46.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 47.2% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 74.1% vs 48.7% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 50.3% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 76.1% vs 50.3% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 77.7% vs 61.2% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 85.1% vs 88.3% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 87.3% vs 47.7% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 90.5% vs 61.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 67.7% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 86.2% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 98.5% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 51.9% vs 54.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 49.1% vs 47.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 40.6% vs 28.8% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 50% vs 23.1% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 36.8% vs 19.2% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 28.6% vs 14.9% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 89.2% vs 89.2% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 90.0% vs 83.3% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 91.7% vs 90.8% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 90.9% vs 89.2% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 89.2% vs 87.3% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 88.8% vs 91.3% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 90% vs 86.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 86.9% vs 81.0% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 83.2% vs 50% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 84.6% vs 58.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 84.2% vs 57.8% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 79.6% vs 54.9% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 73.8% vs 49.3% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 63.8% vs 34.5% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 47.8% vs 19.3% wk 2 · n 279 · Phase 4 · secondary NCT00848354
ACR50—Not reported62.1% vs 36.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
65 other results
  • 57.7% vs 39.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 58.8% vs 36.9% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 59.3% vs 34.7% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 54.4% vs 32.4% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 50.5% vs 30.7% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 44% vs 26.1% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 42.3% vs 23.9% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 15.3% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 22.5% vs 4% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 16% vs 2.3% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 59.4% vs 36.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 57.3% vs 39.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 36.9% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 34.7% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 53.6% vs 32.4% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 30.7% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 26.1% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 47.4% vs 23.9% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 38.5% vs 15.3% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 4% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 14.7% vs 2.3% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · primary NCT00848354
  • 62.5% vs 25.9% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 62.5% vs 27.4% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 63% vs 26.9% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 59% vs 27.9% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 62% vs 28.9% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 58% vs 33.5% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 60.5% vs 41% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 74.1% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 57.2% vs 25.9% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 58.7% vs 27.4% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 53.7% vs 26.9% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 55.7% vs 27.9% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 56.2% vs 28.9% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 59.2% vs 33.5% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 57.9% vs 41% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 70.6% vs 74.1% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 76.2% vs 44.6% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 85.7% vs 50.8% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 50.8% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 87.3% vs 73.8% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 92.1% vs 95.4% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 33% vs 28.8% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 29.2% vs 28.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 30.2% vs 22.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 20.8% vs 12.5% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 19.8% vs 4.8% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 13.2% vs 4.8% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 3% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 70.5% vs 65% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 72.6% vs 59.2% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 61.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 60.8% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 67.3% vs 58.7% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 68.5% vs 62.7% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 65.8% vs 60.3% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 67.3% vs 53.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 59.1% vs 27.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 56.3% vs 24.6% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 52.3% vs 21.1% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 42.3% vs 16.9% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 31.5% vs 8.4% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 15.8% vs 2.9% wk 2 · n 279 · Phase 4 · secondary NCT00848354
ACR70—Not reported36.3% vs 15.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
64 other results
  • 36.3% vs 18.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 14.8% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 31.3% vs 11.9% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 25.8% vs 11.9% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 25.3% vs 13.1% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 18.7% vs 9.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 15.4% vs 9.7% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 11% vs 2.8% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 8.2% vs 0.6% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 3.8% vs 0% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 33.9% vs 15.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 34.4% vs 18.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 31.3% vs 14.8% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 11.9% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 25.5% vs 11.9% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 25% vs 13.1% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 17.7% vs 9.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 21.9% vs 9.7% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 15.1% vs 2.8% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 7.8% vs 0.6% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 4.2% vs 0% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 35.5% vs 11.2% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 34% vs 10.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 32% vs 10.7% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 33% vs 10.2% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 31% vs 10.2% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 28% vs 9.6% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 28.7% vs 17.6% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 42% vs 33% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 31.3% vs 11.2% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 30.3% vs 10.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.7% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 28.9% vs 10.2% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.2% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 30.8% vs 9.6% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 27.9% vs 17.6% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 33.3% vs 33% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 69.8% vs 38.5% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 74.6% vs 38.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 77.8% vs 36.9% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 73% vs 56.9% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 82.5% vs 80% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 16% vs 12.5% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 17% vs 10.6% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 8.5% vs 9.6% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 1% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 0% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 49.0% vs 40% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 48.5% vs 35% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 49.0% vs 36.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 53.1% vs 38.3% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 41.9% vs 34.1% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 39.6% vs 34.1% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 45% vs 32.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 40.4% vs 30.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 34.8% vs 11.3% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 30.1% vs 10.6% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 27.6% vs 9.2% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 20.1% vs 4.2% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 16.1% vs 3.5% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 7.2% vs 2.1% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 3.6% vs 0.7% wk 2 · n 279 · Phase 4 · secondary NCT00848354
DAS28-CRP remission—Not reported54.5% vs 69.1%vs Standard COBRA-Slim Inductionwk 104 · n 55NCT03649061
1 other result
  • 58.2% vs 43.6% wk 28 · n 55 · Phase 4 · secondary NCT03649061
HAQ-DI, change—Not reported-0.6 vs -0.3vs Methotrexate25 mg · wk 52 · n 182NCT00445770
31 other results
  • -0.6 vs -0.3 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • -0.4 vs -0.1 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.4 wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.4 wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.3 wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.2 wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.1 wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • -0.8 vs -0.5 wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 0.9 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.8 vs 0.7 wk 28 · n 55 · Phase 4 · secondary NCT03649061
Modified Sharp score, change—Not reported3.3 vs 9.8vs Methotrexate25 mg · wk 52 · n 181NCT00445770
11 other results
  • 5.2 vs 9.8 10 mg · wk 52 · n 190 · Phase 3 · primary NCT00445770
  • 1.7 vs 5.1 25 mg · wk 24 · n 181 · Phase 3 · secondary NCT00445770
  • 2.4 vs 5.1 10 mg · wk 24 · n 190 · Phase 3 · secondary NCT00445770
  • 0 vs 0.5 wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 0 vs -1 50 mg · wk 48 · n 19 · Phase 4 · secondary NCT00858780
  • 0 vs -1 25 mg · wk 48 · n 22 · Phase 4 · secondary NCT00858780
  • 7 vs 7.3 wk 102 · n 159 · Phase 4 · secondary NCT00259610
  • 4.8 vs 7.3 wk 102 · n 166 · Phase 4 · secondary NCT00259610
  • 0.4 vs 1.4 wk 24 · n 247 · Phase 4 · secondary NCT00848354
  • 0.8 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.3 vs 0.5 wk 52 · n 55 · Phase 4 · secondary NCT03649061

ACR20

adalimumab-aacf (Idacio)
—Not reported
etanercept
78.6% vs 62.5%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
63 other results
  • 79.7% vs 59.1% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 59.7% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 80.8% vs 58% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 56.3% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 78.6% vs 58.5% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 75.3% vs 51.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 77.5% vs 48.3% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 68.7% vs 43.2% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 56.9% vs 27.3% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 49.4% vs 16.1% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 75.9% vs 62.5% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 76.4% vs 59.1% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 78.5% vs 59.7% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 79.1% vs 58% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 77% vs 56.3% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 75.4% vs 58.5% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 73.8% vs 51.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 70.2% vs 48.3% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 68.1% vs 43.2% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 55.5% vs 27.3% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 54% vs 16.1% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 75.5% vs 48.7% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 79.5% vs 46.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 78% vs 47.2% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 48.7% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 75% vs 50.3% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 77% vs 50.3% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 76.9% vs 61.2% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 86.5% vs 88.3% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 74.6% vs 48.7% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 77.6% vs 46.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 47.2% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 74.1% vs 48.7% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 74.6% vs 50.3% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 76.1% vs 50.3% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 77.7% vs 61.2% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 85.1% vs 88.3% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 87.3% vs 47.7% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 90.5% vs 61.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 67.7% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 86.2% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 96.8% vs 98.5% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 51.9% vs 54.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 49.1% vs 47.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 40.6% vs 28.8% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 50% vs 23.1% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 36.8% vs 19.2% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 28.6% vs 14.9% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 89.2% vs 89.2% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 90.0% vs 83.3% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 91.7% vs 90.8% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 90.9% vs 89.2% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 89.2% vs 87.3% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 88.8% vs 91.3% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 90% vs 86.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 86.9% vs 81.0% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 83.2% vs 50% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 84.6% vs 58.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 84.2% vs 57.8% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 79.6% vs 54.9% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 73.8% vs 49.3% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 63.8% vs 34.5% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 47.8% vs 19.3% wk 2 · n 279 · Phase 4 · secondary NCT00848354

ACR50

adalimumab-aacf (Idacio)
—Not reported
etanercept
62.1% vs 36.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
65 other results
  • 57.7% vs 39.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 58.8% vs 36.9% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 59.3% vs 34.7% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 54.4% vs 32.4% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 50.5% vs 30.7% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 44% vs 26.1% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 42.3% vs 23.9% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 15.3% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 22.5% vs 4% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 16% vs 2.3% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 59.4% vs 36.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 57.3% vs 39.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 36.9% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 60.4% vs 34.7% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 53.6% vs 32.4% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 30.7% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 50% vs 26.1% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 47.4% vs 23.9% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 38.5% vs 15.3% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 4% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 14.7% vs 2.3% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · primary NCT00848354
  • 62.5% vs 25.9% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 62.5% vs 27.4% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 63% vs 26.9% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 59% vs 27.9% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 62% vs 28.9% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 58% vs 33.5% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 60.5% vs 41% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 76.5% vs 74.1% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 57.2% vs 25.9% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 58.7% vs 27.4% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 53.7% vs 26.9% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 55.7% vs 27.9% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 56.2% vs 28.9% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 59.2% vs 33.5% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 57.9% vs 41% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 70.6% vs 74.1% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 76.2% vs 44.6% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 85.7% vs 50.8% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 93.7% vs 50.8% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 87.3% vs 73.8% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 92.1% vs 95.4% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 33% vs 28.8% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 29.2% vs 28.8% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 30.2% vs 22.1% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 20.8% vs 12.5% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 19.8% vs 4.8% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 13.2% vs 4.8% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 3% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 70.5% vs 65% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 72.6% vs 59.2% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 61.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 73.4% vs 60.8% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 67.3% vs 58.7% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 68.5% vs 62.7% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 65.8% vs 60.3% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 67.3% vs 53.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 62.0% vs 23.2% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 59.1% vs 27.5% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 56.3% vs 24.6% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 52.3% vs 21.1% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 42.3% vs 16.9% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 31.5% vs 8.4% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 15.8% vs 2.9% wk 2 · n 279 · Phase 4 · secondary NCT00848354

ACR70

adalimumab-aacf (Idacio)
—Not reported
etanercept
36.3% vs 15.9%vs Methotrexate25 mg · wk 52 · n 182NCT00445770
64 other results
  • 36.3% vs 18.2% 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • 35.7% vs 14.8% 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • 31.3% vs 11.9% 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • 25.8% vs 11.9% 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • 25.3% vs 13.1% 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • 18.7% vs 9.7% 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • 15.4% vs 9.7% 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • 11% vs 2.8% 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • 8.2% vs 0.6% 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • 3.8% vs 0% 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • 33.9% vs 15.9% 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • 34.4% vs 18.2% 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • 31.3% vs 14.8% 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • 28.1% vs 11.9% 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • 25.5% vs 11.9% 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • 25% vs 13.1% 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • 17.7% vs 9.7% 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • 21.9% vs 9.7% 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • 15.1% vs 2.8% 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • 7.8% vs 0.6% 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • 4.2% vs 0% 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • 35.5% vs 11.2% 50 mg · wk 88 · n 200 · Phase 4 · secondary NCT00565409
  • 34% vs 10.7% 50 mg · wk 80 · n 200 · Phase 4 · secondary NCT00565409
  • 32% vs 10.7% 50 mg · wk 72 · n 200 · Phase 4 · secondary NCT00565409
  • 33% vs 10.2% 50 mg · wk 64 · n 200 · Phase 4 · secondary NCT00565409
  • 31% vs 10.2% 50 mg · wk 56 · n 200 · Phase 4 · secondary NCT00565409
  • 28% vs 9.6% 50 mg · wk 48 · n 200 · Phase 4 · secondary NCT00565409
  • 28.7% vs 17.6% 50 mg · wk 40 · n 200 · Phase 4 · secondary NCT00565409
  • 42% vs 33% 50 mg · wk 36 · n 200 · Phase 4 · secondary NCT00565409
  • 31.3% vs 11.2% 25 mg · wk 88 · n 201 · Phase 4 · secondary NCT00565409
  • 30.3% vs 10.7% 25 mg · wk 80 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.7% 25 mg · wk 72 · n 201 · Phase 4 · secondary NCT00565409
  • 28.9% vs 10.2% 25 mg · wk 64 · n 201 · Phase 4 · secondary NCT00565409
  • 31.3% vs 10.2% 25 mg · wk 56 · n 201 · Phase 4 · secondary NCT00565409
  • 30.8% vs 9.6% 25 mg · wk 48 · n 201 · Phase 4 · secondary NCT00565409
  • 27.9% vs 17.6% 25 mg · wk 40 · n 201 · Phase 4 · secondary NCT00565409
  • 33.3% vs 33% 25 mg · wk 36 · n 201 · Phase 4 · secondary NCT00565409
  • 69.8% vs 38.5% wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 74.6% vs 38.5% wk 76 · n 63 · Phase 4 · secondary NCT00913458
  • 77.8% vs 36.9% wk 64 · n 63 · Phase 4 · secondary NCT00913458
  • 73% vs 56.9% wk 56 · n 63 · Phase 4 · secondary NCT00913458
  • 82.5% vs 80% wk 52 · n 63 · Phase 4 · secondary NCT00913458
  • 16% vs 12.5% wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • 17% vs 10.6% wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • 8.5% vs 9.6% wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 1% wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • 5.7% vs 0% wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • 1.9% vs 0% wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • 49.0% vs 40% wk 128 · n 260 · Phase 4 · secondary NCT00848354
  • 48.5% vs 35% wk 115 · n 260 · Phase 4 · secondary NCT00848354
  • 49.0% vs 36.7% wk 102 · n 260 · Phase 4 · secondary NCT00848354
  • 53.1% vs 38.3% wk 89 · n 260 · Phase 4 · secondary NCT00848354
  • 41.9% vs 34.1% wk 76 · n 260 · Phase 4 · secondary NCT00848354
  • 39.6% vs 34.1% wk 63 · n 260 · Phase 4 · secondary NCT00848354
  • 45% vs 32.5% wk 50 · n 260 · Phase 4 · secondary NCT00848354
  • 40.4% vs 30.2% wk 37 · n 260 · Phase 4 · secondary NCT00848354
  • 34.8% vs 11.3% wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 30.1% vs 10.6% wk 20 · n 279 · Phase 4 · secondary NCT00848354
  • 27.6% vs 9.2% wk 16 · n 279 · Phase 4 · secondary NCT00848354
  • 20.1% vs 4.2% wk 12 · n 279 · Phase 4 · secondary NCT00848354
  • 16.1% vs 3.5% wk 8 · n 279 · Phase 4 · secondary NCT00848354
  • 7.2% vs 2.1% wk 4 · n 279 · Phase 4 · secondary NCT00848354
  • 3.6% vs 0.7% wk 2 · n 279 · Phase 4 · secondary NCT00848354

DAS28-CRP remission

adalimumab-aacf (Idacio)
—Not reported
etanercept
54.5% vs 69.1%vs Standard COBRA-Slim Inductionwk 104 · n 55NCT03649061
1 other result
  • 58.2% vs 43.6% wk 28 · n 55 · Phase 4 · secondary NCT03649061

HAQ-DI, change

adalimumab-aacf (Idacio)
—Not reported
etanercept
-0.6 vs -0.3vs Methotrexate25 mg · wk 52 · n 182NCT00445770
31 other results
  • -0.6 vs -0.3 25 mg · wk 48 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 40 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 32 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 24 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 25 mg · wk 20 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 16 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 25 mg · wk 12 · n 182 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 25 mg · wk 8 · n 182 · Phase 3 · secondary NCT00445770
  • -0.4 vs -0.1 25 mg · wk 4 · n 182 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 25 mg · wk 2 · n 182 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 52 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 48 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 40 · n 192 · Phase 3 · secondary NCT00445770
  • -0.6 vs -0.3 10 mg · wk 32 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 24 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 20 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 16 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.3 10 mg · wk 12 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.2 10 mg · wk 8 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 4 · n 192 · Phase 3 · secondary NCT00445770
  • -0.3 vs -0.1 10 mg · wk 2 · n 192 · Phase 3 · secondary NCT00445770
  • -0.5 vs -0.4 wk 24 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.4 wk 20 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.3 wk 16 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 12 · n 106 · Phase 4 · secondary NCT01313208
  • -0.4 vs -0.2 wk 8 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.2 wk 4 · n 106 · Phase 4 · secondary NCT01313208
  • -0.3 vs -0.1 wk 2 · n 106 · Phase 4 · secondary NCT01313208
  • -0.8 vs -0.5 wk 24 · n 279 · Phase 4 · secondary NCT00848354
  • 0.9 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.8 vs 0.7 wk 28 · n 55 · Phase 4 · secondary NCT03649061

Modified Sharp score, change

adalimumab-aacf (Idacio)
—Not reported
etanercept
3.3 vs 9.8vs Methotrexate25 mg · wk 52 · n 181NCT00445770
11 other results
  • 5.2 vs 9.8 10 mg · wk 52 · n 190 · Phase 3 · primary NCT00445770
  • 1.7 vs 5.1 25 mg · wk 24 · n 181 · Phase 3 · secondary NCT00445770
  • 2.4 vs 5.1 10 mg · wk 24 · n 190 · Phase 3 · secondary NCT00445770
  • 0 vs 0.5 wk 91 · n 63 · Phase 4 · secondary NCT00913458
  • 0 vs -1 50 mg · wk 48 · n 19 · Phase 4 · secondary NCT00858780
  • 0 vs -1 25 mg · wk 48 · n 22 · Phase 4 · secondary NCT00858780
  • 7 vs 7.3 wk 102 · n 159 · Phase 4 · secondary NCT00259610
  • 4.8 vs 7.3 wk 102 · n 166 · Phase 4 · secondary NCT00259610
  • 0.4 vs 1.4 wk 24 · n 247 · Phase 4 · secondary NCT00848354
  • 0.8 vs 0.7 wk 104 · n 55 · Phase 4 · secondary NCT03649061
  • 0.3 vs 0.5 wk 52 · n 55 · Phase 4 · secondary NCT03649061
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-aacf (Idacio): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-aacf (Idacio): 0 of 4 rows · etanercept: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricetanercept
Dropout rate
—0.4 mg/kga
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 44 more results
62.5%Adult Participants
NCT00357903 · Phase 3 · monotherapy
74.1%Pediatric Participants
NCT00357903 · Phase 3 · monotherapy
—Pediatric Subjects
NCT00357903 · Phase 3 · monotherapy
—Total Adults
NCT00357903 · Phase 3 · monotherapy
16.4%
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
—
NCT01578850 · Phase 4 · registry result, not featured evidence
4.7%Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Etanercept-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Placebo-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
4.3%Etanercept + Methotrexate
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 1
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
29.9%Etanercept + Methotrexate
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
49%Etanercept Alone
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
36.6%50 mg QW
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25 + MTX (Phase 2)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25+MTX (Phase 3)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
—25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
9.4%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—25 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
9.5%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
40.5%ETN Alone
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
16.9%ETN+MTX
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
31.1%
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
2%
NCT00422227 · Phase 4 · registry result, not featured evidence
19.3%Year 1 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—Open Label Rescue: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
31.3%Open Label Run-In: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—
NCT02986139 · Phase 3 · registry result, not featured evidence
13.3%
NCT02378506 · Phase 3 · registry result, not featured evidence
17%25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
18.2%10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
8%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
6.7%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
2.4%50 mg once weekly
NCT00418717 · Phase 3 · registry result, not featured evidence
14.3%
NCT00361634 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—0.4 mg/kga
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 44 more results
15%Adult Participants
NCT00357903 · Phase 3 · monotherapy
6.9%Pediatric Participants
NCT00357903 · Phase 3 · monotherapy
—Pediatric Subjects
NCT00357903 · Phase 3 · monotherapy
—Total Adults
NCT00357903 · Phase 3 · monotherapy
—
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
—
NCT01578850 · Phase 4 · registry result, not featured evidence
1.9%Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Etanercept-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Placebo-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
1.8%Etanercept + Methotrexate
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 1
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
—Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
5.6%Etanercept + Methotrexate
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
9.2%Etanercept Alone
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
6.5%50 mg QW
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25 + MTX (Phase 2)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—E25+MTX (Phase 3)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
—25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
2%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
—25 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
2.4%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
5.4%ETN Alone
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
1.3%ETN+MTX
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
4.5%
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
1.5%
NCT00422227 · Phase 4 · registry result, not featured evidence
9.9%Year 1 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
—Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—Open Label Rescue: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
0.8%Open Label Run-In: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
—
NCT02986139 · Phase 3 · registry result, not featured evidence
7.4%
NCT02378506 · Phase 3 · registry result, not featured evidence
10.4%25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
7.8%10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
5.8%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
4.1%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
—50 mg once weekly
NCT00418717 · Phase 3 · registry result, not featured evidence
—
NCT00361634 · Phase 1 · registry result, not featured evidence
Serious AEs
4%0.4 mg/kga
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 44 more results
—Adult Participants
NCT00357903 · Phase 3 · monotherapy
—Pediatric Participants
NCT00357903 · Phase 3 · monotherapy
27.6%Pediatric Subjects
NCT00357903 · Phase 3 · monotherapy
50.4%Total Adults
NCT00357903 · Phase 3 · monotherapy
9.1%
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
0%
NCT01578850 · Phase 4 · registry result, not featured evidence
—Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
3.8%Etanercept-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
2.9%Placebo-Etanercept
NCT01313208 · Phase 4 · registry result, not featured evidence
—Etanercept + Methotrexate
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
3.6%Etanercept + Methotrexate Phase 1
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
6.5%Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
4.6%Etanercept + Methotrexate Phase 2
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
15.9%Etanercept + Methotrexate
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
11.2%Etanercept Alone
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
9.2%50 mg QW
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
4.8%E25 + MTX (Phase 2)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
0%E25+MTX (Phase 3)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
4.3%50 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
3.7%25 mg
NCT00858780 · Phase 4 · registry result, not featured evidence
4.6%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
6.4%50 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
3.5%25 mg
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
4.8%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
2.8%ETN Alone
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
11.8%ETN+MTX
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
14.3%
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
3%
NCT00422227 · Phase 4 · registry result, not featured evidence
—Year 1 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 E+M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
—Year 1 M / Year 2 E+M
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
3%Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
3.8%Double-Blind Treatment: Etanercept
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
3.9%Open Label Rescue: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
3.8%Open Label Run-In: Etanercept Plus
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence
4.8%
NCT02378506 · Phase 3 · registry result, not featured evidence
6%25 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
4.2%10 mg
NCT00445770 · Phase 3 · registry result, not featured evidence
5.5%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
2.9%50 mg
NCT00459706 · Phase 3 · registry result, not featured evidence
—50 mg once weekly
NCT00418717 · Phase 3 · registry result, not featured evidence
0%
NCT00361634 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
0.4 mg/kga
upper respiratory tract infection 40% (placebo 15.4%)
headache 20% (placebo 11.5%)
gastroenteritis 12% (placebo 3.8%)
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 40 more results
upper respiratory tract infection 62.1%
headache 34.5%
pharyngitis 22.4%
NCT00357903 · Phase 3 · monotherapy
upper respiratory tract infection 35.6%
sinusitis 20.8%
bronchitis 15.3%
NCT00357903 · Phase 3 · monotherapy
nausea 25.5%
fatigue 23.6%
hepatic function abnormal 16.4%
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 2.4% (placebo 5.1%)
NCT01578850 · Phase 4 · registry result, not featured evidence
injection site erythema 12.3%
rheumatoid arthritis 11.3%
headache 8.5%
NCT01313208 · Phase 4 · registry result, not featured evidence
headache 15.4%
upper respiratory tract infection 12.5%
nasopharyngitis 11.5%
NCT01313208 · Phase 4 · registry result, not featured evidence
bronchitis 6.4%
influenza 5.3%
nasopharyngitis 5%
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
bronchitis 4.2%
influenza 4.2%
nasopharyngitis 4.2%
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
bronchitis 7.1%
nasopharyngitis 4.6%
urinary tract infection 4.6%
NCT00848354 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 17.8%
nasopharyngitis 11.2%
sinusitis 10.3%
NCT00654368 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 13.3%
nasopharyngitis 10.2%
headache 9.2%
NCT00654368 · Phase 4 · registry result, not featured evidence · monotherapy
50 mg QW
nasopharyngitis 12.7% (placebo 4.6%)
nausea 12.7% (placebo 0%)
headache 6.5% (placebo 0%)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.9% (placebo 4.6%)
upper respiratory tract infection 6.3% (placebo 4.6%)
rheumatoid arthritis 3.2% (placebo 9.2%)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 18.9% (placebo 9.2%)
nasopharyngitis 5.7% (placebo 4.6%)
alanine aminotransferase increased 0% (placebo 0%)
NCT00913458 · Phase 4 · registry result, not featured evidence · combination
50 mg
nasopharyngitis 26.1% (placebo 8.7%)
upper respiratory tract infection 26.1% (placebo 8.7%)
back pain 13% (placebo 0%)
NCT00858780 · Phase 4 · registry result, not featured evidence
25 mg
nasopharyngitis 29.6% (placebo 8.7%)
arthralgia 11.1% (placebo 0%)
gastroenteritis 11.1% (placebo 0%)
NCT00858780 · Phase 4 · registry result, not featured evidence
50 mg
headache 6.1% (placebo 0%)
nasopharyngitis 5.8% (placebo 5%)
bronchitis 0% (placebo 3%)
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
50 mg
nasopharyngitis 8.9% (placebo 5%)
bronchitis 5.9% (placebo 3%)
pharyngitis 1.5% (placebo 5.5%)
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
25 mg
bronchitis 5.4% (placebo 3%)
nasopharyngitis 5% (placebo 5%)
pharyngitis 2.5% (placebo 5.5%)
NCT00565409 · Phase 4 · registry result, not featured evidence · combination
liver function test elevation 7.1%
NCT00443430 · Phase 4 · registry result, not featured evidence · combination
upper airway viral infection 40.8%
rash 26.8%
injection site reaction 22.5%
NCT00688103 · Phase 4 · registry result, not featured evidence · monotherapy
upper airway viral infection 43.4%
injection site reaction 11.8%
gastroentelitis 10.5%
NCT00688103 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 53.7% (placebo 57.3%)
joint pain 27% (placebo 22.4%)
dermatalogic eruption 14.8% (placebo 14.5%)
NCT00259610 · Phase 4 · registry result, not featured evidence · combination
upper respiratory tract infection 13.7%
alanine aminotransferase increased 5.6%
aspartate aminotransferase increased 3.6%
NCT00422227 · Phase 4 · registry result, not featured evidence
administration site conditions 24.5%
nausea 19.3%
investigations 17.9%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
infections and infestations 44.1%
injury, poisoning and procedural complications 13.5%
nasopharyngitis 9%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
infections and infestations 42.3%
injury, poisoning and procedural complications 11.7%
nasopharyngitis 9%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
infections and infestations 36.7%
injury, poisoning and procedural complications 12.2%
nasopharyngitis 11.1%
NCT00195494 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis 7.1%
bronchitis 3%
upper respiratory tract infection 3%
NCT02373813 · Phase 3 · registry result, not featured evidence · monotherapy
bronchitis 7.5%
rheumatoid arthritis 5.7%
upper respiratory tract infection 1.9%
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 6.8%
rheumatoid arthritis 1.9%
bronchitis 0%
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 5.4%
bronchitis 1.6%
rheumatoid arthritis 0.8%
NCT02373813 · Phase 3 · registry result, not featured evidence · combination
hypoaesthesia 1.9%
pain in extremity 1.9%
cellulitis 0.9%
NCT02986139 · Phase 3 · registry result, not featured evidence
injection site erythema 10.7%
nasopharyngitis 7%
upper respiratory tract infection 7%
NCT02378506 · Phase 3 · registry result, not featured evidence
25 mg
nasopharyngitis 20.3%
upper respiratory tract infection 11.5%
pharyngitis 8.2%
NCT00445770 · Phase 3 · registry result, not featured evidence
10 mg
nasopharyngitis 23.4%
upper respiratory tract infection 10.4%
pharyngitis 9.4%
NCT00445770 · Phase 3 · registry result, not featured evidence
50 mg
injection site reaction 14.2%
injection site erythema 7.7%
nasopharyngitis 6.8%
NCT00459706 · Phase 3 · registry result, not featured evidence
50 mg
injection site reaction 17.6%
injection site erythema 9.3%
nasopharyngitis 8.3%
NCT00459706 · Phase 3 · registry result, not featured evidence
50 mg once weekly
infections and infestations 28.6%
dizziness 7.1%
headache 4.8%
NCT00418717 · Phase 3 · registry result, not featured evidence
dry skin 23.1%
injection site reaction 23.1%
cough 15.4%
NCT00361634 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

etanercept

Disease Flare 28% (n=25) vs 81% (n=26) placebo0.4 mg/kg
responder rate · % of participants
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3
show 1 more result
52.1% (n=163) vs 79.8% (n=168) placebo @ 52wk
NCT01578850 · Phase 4 · registry result, not featured evidence
Time to Flare Median 3.81 vs 0.92 placebo months0.4 mg/kg
time to event · months
NCT03780959 · Phase 2/3 · monotherapy · Rheumatoid Arthritis · phase 2/3 · converted to months from 116 days as posted
Tender Joint 9.55 Joints @ 52wk
event count · Joints
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
show 1 more result
11.6 Joints @ 52wk
NCT00357903 · Phase 3 · monotherapy
Swollen Joint 9.14 Joints @ 52wk
event count · Joints
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
show 1 more result
11.93 Joints @ 52wk
NCT00357903 · Phase 3 · monotherapy
HAQ-DI 0.96 score @ 52wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
CHAQ 1.08 score @ 52wk
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy
ACR20 66.4% (n=560) @ 12wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy · converted to % from 372 Participants as posted
JRA DOI 30 86.8% (n=53) @ 12wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00357903 · Phase 3 · monotherapy · converted to % from 46 Participants as posted
DAS28-CRP AUC 300.7 vs 297.4 Standard COBRA-Slim Induction score @ 104wk
absolute value · score
NCT03649061 · Phase 4 · registry result, not featured evidence · combination
DAS28 (CRP) Remission 58.2% (n=55) vs 43.6% (n=55) Standard COBRA-Slim Induction @ 28wk
responder rate · % of participants
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 32 participants as posted
show 1 more result
54.5% (n=55) vs 69.1% (n=55) Standard COBRA-Slim Induction @ 104wk*
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 30 participants as posted
EULAR Good 45.5% (n=55) vs 47.3% (n=55) Standard COBRA-Slim Induction @ 28wk
responder rate · % of participants
Good Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 25 participants as posted
show 1 more result
61.8% (n=55) vs 76.4% (n=55) Standard COBRA-Slim Induction @ 104wk*
Good Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 34 participants as posted
EULAR Moderate 72.7% (n=55) vs 74.5% (n=55) Standard COBRA-Slim Induction @ 28wk
responder rate · % of participants
Moderate Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 40 participants as posted
show 1 more result
89.1% (n=55) vs 94.5% (n=55) Standard COBRA-Slim Induction @ 104wk*
Moderate Response
NCT03649061 · Phase 4 · registry result, not featured evidence · combination · converted to % from 49 participants as posted

+ 238 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aacf (Idacio)'s landscape · etanercept's landscape